PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 07:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease...
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
November 08, 2021 08:30 ET
|
PDS Biotechnology Corporation
Advances Next Phase of Versamune® Oncology Pipeline FLORHAM PARK, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company...
PDS Biotechnology Welcomes Matthew Hill as Chief Financial Officer
October 06, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
October 04, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the Benzinga Healthcare Conference
September 27, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”, Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer...
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Advanced Head and Neck Cancer
September 20, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 15, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 13, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
September 09, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology to Present at the HC Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:30 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...